12:00 AM
Aug 25, 2008
 |  BC Week In Review  |  Clinical News  |  Clinical Results

KRP-104: Phase IIa data

Top-line data from a double-blind, placebo-controlled, U.S. and Indian Phase IIa trial in 220 patients with Type II diabetes inadequately controlled on metformin alone, showed that KRP-104 administered twice-daily at 60 mg or once-daily at 120...

Read the full 157 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >